Cancer Research and Treatment

Original Article

Analysis of Biologically Equivalent Dose of Stereotactic Body Radiotherapy for Primary and Metastatic Lung Tumors: Sungkwang Park, Sanghwa Urm, Heunglae Cho; Cancer Res Treat. 2014;46(4):403-410. Published online July 17, 2014; DOI: https://doi.org/10.4143/crt.2013.168

Purpose
The purpose of this study was to determine the optimal biologically equivalent dose (BED) for stereotactic body radiotherapy (SBRT) by comparing local control rates in proportion to various total doses and fractionation schedules. Materials and Methods Thirty-four patients with early non-small-cell lung cancer and a single metastatic lung tumor were included in this study. Differences in local control rates were evaluated according to gender, primary tumor site, response, tumor size, and BED. For comparison of BEDs, the prescribed dose for SBRT was stratified according to three groups: high (BED > 146 Gy), medium to high (BED, 106 to 146 Gy), and low to medium (BED < 106 Gy). Results For all patients, the overall local control rate was 85.3% at two years after treatment. Five local recurrences were observed, and, notably, all of them were observed in the low to medium BED group. Significantly higher local control rates were observed for patients with a complete response than for those with a partial response or stable disease (p < 0.001). Twenty-six patients with a tumor size of < 3 cm showed no dose-response relationship in the low to medium, medium to high, and high BED groups, whereas eight patients with a tumor size of ≥ 3 cm showed a significant dose-response relationship. The observed 2-year local recurrence-free survival rates in patients with a tumor size of < 3 cm and in those with a tumor size of ≥ 3 cm were 96.2% and 50.0%, respectively, which were significantly different (p=0.007). Conclusion BED > 100 Gy is required in order to achieve a > 85% local control rate regardless of tumor size. The optimal dose for small tumors of < 3 cm appears to be within a range below 150 Gy BED. Escalation of BED to high levels (> 150 Gy) may be required for patients with a tumor size larger than 3 cm.

Citations

Citations to this article as recorded by

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study
Julianne Cynthia de Ruiter, Vincent van der Noort, Judi Nani Annet van Diessen, Egbert Frederik Smit, Ronald Alphons Maria Damhuis, Koen Johan Hartemink, M.I. Amir, H. van Berkum, H. Bertens, M. Bindels, E.M. Bongers, R.C. Boshuizen, K. de Brake-de Jong,
Lung Cancer.2024; 191: 107792. CrossRef
Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group
Gyu Sang Yoo, Sunmin Park, Chai Hong Rim, Won Kyung Cho, Ah Ram Chang, Young Seok Kim, Yong Chan Ahn, Eui Kyu Chie
Current Oncology.2024; 31(6): 3239. CrossRef
Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis
Gustavo A. Viani, Andre G. Gouveia, Alexander V. Louie, Fabio Arcidiacono, Charles B. Simone, Theodoros Tsakiridis, Ana Carolina Hamamura, Paola Anselmo, Fabio Y. Moraes
Radiotherapy and Oncology.2024; 201: 110439. CrossRef
Treatment outcomes of stereotactic body radiation therapy for pulmonary metastasis from sarcoma: a multicenter, retrospective study
Tae Hoon Lee, Hak Jae Kim, Jin Ho Kim, Mi-Sook Kim, Won Il Jang, Eunji Kim, Kyung Su Kim
Radiation Oncology.2023;[Epub] CrossRef
Dosimetric evaluation of SBRT treatment plans of non-central lung tumours: clinical experience
Ernest Osei, Johnson Darko, Steph Swanson, Katrina Fleming, Ronald Snelgrove, Anmol Bhangu, Darin Gopaul
Journal of Radiotherapy in Practice.2022; 21(2): 179. CrossRef
Use of Multi-Site Radiation Therapy for Systemic Disease Control
Roshal R. Patel, Vivek Verma, Hampartsoum B. Barsoumian, Matthew S. Ning, Stephen G. Chun, Chad Tang, Joe Y. Chang, Percy P. Lee, Saumil Gandhi, Peter Balter, Joe Dan Dunn, Dawei Chen, Nahum Puebla-Osorio, Maria Angelica Cortez, James W. Welsh
International Journal of Radiation Oncology*Biology*Physics.2021; 109(2): 352. CrossRef
Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer—Ready for Prime Time?
David P. Horowitz, Karyn Goodman, Lisa A. Kachnic
JAMA Oncology.2021; 7(5): 687. CrossRef
Evidence-Based Planning Target Volume Margin Reduction for Modern Lung Stereotactic Ablative Radiation Therapy Using Deformable Registration
Katie Jasper, Baochang Liu, Robert Olson, Quinn Matthews
Advances in Radiation Oncology.2021; 6(6): 100750. CrossRef
Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus
William Tyler Turchan, Sean P. Pitroda, Ralph R. Weichselbaum
Clinical Cancer Research.2021; 27(19): 5188. CrossRef
Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms
Jingjing Kang, Matthew S. Ning, Han Feng, Hongqi Li, Houda Bahig, Eric D. Brooks, James W. Welsh, Rui Ye, Hongyu Miao, Joe Y. Chang
International Journal of Radiation Oncology*Biology*Physics.2020; 106(1): 90. CrossRef
Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation
Stephen R. Grant, Xiudong Lei, Kenneth R. Hess, Grace L. Smith, Surena F. Matin, Christopher G. Wood, Quynh Nguyen, Steven J. Frank, Mitchell S. Anscher, Benjamin D. Smith, Jose A. Karam, Chad Tang
Advances in Radiation Oncology.2020; 5(3): 495. CrossRef
The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma
Cameron M. Callaghan, Steven N. Seyedin, Imran H. Mohiuddin, Kelli L. Hawkes, Michael S. Petronek, Carryn M. Anderson, John M. Buatti, Mohammed M. Milhem, Varun Monga, Bryan G. Allen
Radiation Research.2020; 194(2): 124. CrossRef
Traitements locaux : indication et résultats dans les stades précoces
L. Padovani, C. Massabeau, J. Khalifa, P. Habert, J.-Y. Gaubert
Revue des Maladies Respiratoires Actualités.2020; 12(2): 2S79. CrossRef
Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy
Jisun Park, Yunseon Choi, Ki Jung Ahn, Sung Kwang Park, Heunglae Cho, Ji Young Lee
Radiation Oncology Journal.2019; 37(1): 30. CrossRef
Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function
Jia-Yang Lu, Pei-Xian Lin, Bao-Tian Huang
Radiation Oncology.2019;[Epub] CrossRef
La radiothérapie stéréotaxique: indication et résultats dans les stades précoces
C. Massabeau, J. Khalifa
Revue des Maladies Respiratoires Actualités.2019; 11(3): 255. CrossRef
GTV volume estimation using different mode of computer tomography for lung tumors in stereotactic body radiation therapy
Ramaa Lingaiah, Md Abbas Ali, Ummay Kulsum, Muhtasim Aziz Muneem, Karthick Raj Mani, Sharif Ahmed, Md. Shakilur Rahman, M Salahuddin
Polish Journal of Medical Physics and Engineering.2019; 25(1): 29. CrossRef
Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study
Wan Jeon, Sung-Ja Ahn, Young-Chul Kim, In-Jae Oh, Chul-Kyu Park, Jae-Uk Jeong, Mee Sun Yoon, Ju-Young Song, Taek-Keun Nam, Woong-Ki Chung
Japanese Journal of Clinical Oncology.2018; 48(2): 144. CrossRef
Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions
Meisong Ding, William Zollinger, Robert Ebeling, David Heard, Ryan Posey
Journal of Applied Clinical Medical Physics.2018; 19(6): 226. CrossRef
Oligometastatische Erkrankung des nichtkleinzelligen Lungenkarzinoms
Severin Schmid, Bernward Passlick, Martin Stuschke, Frank Griesinger
Der Onkologe.2018; 24(12): 992. CrossRef
A feasibility study of spatiotemporally integrated radiotherapy using the LQ model
M Kim, M H Phillips
Physics in Medicine & Biology.2018; 63(24): 245016. CrossRef
Dosimetric comparison of deep inspiration breath hold and free breathing technique in stereotactic body radiotherapy for localized lung tumor using Flattening Filter Free beam
Karthick Raj Mani, Md. Anisuzzaman Bhuiyan, Md. Mahbub Alam, Sharif Ahmed, Mostafa Aziz Sumon, Ashim Kumar Sengupta, Md. Shakilur Rahman, Md. S. M. Azharul Islam
Polish Journal of Medical Physics and Engineering.2018; 24(1): 15. CrossRef
Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases
J.H. Chang, S. Gandhidasan, R. Finnigan, D. Whalley, R. Nair, A. Herschtal, T. Eade, A. Kneebone, J. Ruben, M. Foote, S. Siva
Clinical Oncology.2017; 29(7): e119. CrossRef
Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy
Bao-Tian Huang, Wu-Zhe Zhang, Li-Li Wu, Pei-Xian Lin, Jia-Yang Lu
BioMed Research International.2017; 2017: 1. CrossRef
The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer
Eduardo Guerrero, Merina Ahmed
Lung Cancer.2016; 92: 22. CrossRef
Hypofractionated radiotherapy for medically inoperable stage I non‐small cell lung cancer
Wei Jiang, Jian‐Yang Wang, Jing‐Bo Wang, Jun Liang, Zhou‐Guang Hui, Xiao‐Zhen Wang, Zong‐Mei Zhou, Lu‐Hua Wang
Thoracic Cancer.2016; 7(3): 296. CrossRef
Lung SBRT through Radiobiology
Aime M. Gloi
International Journal of Medical Physics, Clinical Engineering and Radiation Oncology.2016; 05(01): 78. CrossRef
Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules
Won Kyung Cho, Jae Myoung Noh, Yong Chan Ahn, Dongryul Oh, Hongryull Pyo
Cancer Research and Treatment.2016; 48(4): 1187. CrossRef
Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy
Lina Zhao, Shouhao Zhou, Peter Balter, Chan Shen, Daniel R. Gomez, James D. Welsh, Steve H. Lin, Joe Y. Chang
International Journal of Radiation Oncology*Biology*Physics.2016; 95(4): 1226. CrossRef
Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy
Matthew P. Deek, Sairaman Nagarajan, Sinae Kim, Inaya Ahmed, Shiby Paul, Eli D. Scher, Matthew Listo, Andrew Chen, Joseph Aisner, Sabiha Hussain, Bruce G. Haffty, Salma K. Jabbour
Acta Oncologica.2016; 55(8): 1029. CrossRef
Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain
Shaun U. Din, Eric L. Williams, Andrew Jackson, Kenneth E. Rosenzweig, Abraham J. Wu, Amanda Foster, Ellen D. Yorke, Andreas Rimner
International Journal of Radiation Oncology*Biology*Physics.2015; 93(2): 418. CrossRef
A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization
Minsun Kim, Robert D. Stewart, Mark H. Phillips
Medical Physics.2015; 42(11): 6671. CrossRef
Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy
Bao-Tian Huang, Jia-Yang Lu, Pei-Xian Lin, Jian-Zhou Chen, De-Rui Li, Chuang-Zhen Chen
Scientific Reports.2015;[Epub] CrossRef
A Theoretical Study: Selection of a Personalized Radiotherapy Fractionation Schedule Using Spatiotemporal Optimization
Minsun Kim, Robert Stewart, Mark H Phillips
SSRN Electronic Journal.2015;[Epub] CrossRef

12,795 View
77 Download
35 Web of Science
34 Crossref

First
Prev
Page of 1
Next
Last

Search